SEPTEMBER 21, 2021
Stanislas Veillet tells us in video on the active preparation of the marketing of Sarconeos for the first half of 2022
SEPTEMBER 17, 2021
Biophytis publishes its interim financial report for the first half of 2021 and provides updates on key operational developments and financing transactions SARA-INT: Positive top line results of Phase 2 study demonstrate efficacy of Sarconeos (BIO101) in sarcopenia and support progress into Phase 3 COVA: DMC second interim analysis shows efficacy results in the promising…
SEPTEMBER 15, 2021
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19 Biophytis today announces the recommendation by the Data Monitoring Committee (DMC) to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found…
SEPTEMBER 14, 2021
Biophytis announces its management will participate and meet with investors at the following upcoming events and conferences: H. C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 to 15 – Virtual Amsterdam MidCap EventSeptember 20 to 21 – Virtual Investor Access EventSeptember 27 to 28 – Paris HealthTech Innovation DaysOctober 4 to 5 – Paris European…
ICFSR 2021 – International Conference on Frailty & Sarcopenia Research
SAVE THE DATE THURSAY, SEPTEMBER 30 • ROUNDTABLE 9:00-9:30 AM USA (EST) TIME SARA results will be presented and discussed, in a dedicated session, during the next ICFSR congress SARCONEOS BIO101 IN SARCOPENIA: LESSONS LEARNED FROM THE SARA PROGRAM Biophytis experts : Cendrine Tourette, PhD – Waly Dioh, PhD – Jean Mariani, with the presence…
SEPTEMBER 9, 2021
Biophytis today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.
AUGUST 16, 2021
Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19
AUGUST 13, 2021
Biophytis announces today that it has performed the obligations imposed on it by (i) the judgment of the Commercial Court of Paris (Tribunal de commerce de Paris) of March 16, 2021 and (ii) the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris (Juge de l’exécution du Tribunal Judiciaire…
AUGUST 12, 2021
Interview by Didier Testot Founder to watch on LA BOURSE ET LA VIE TV
AUGUST 2, 2021
Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia